文献速递淋巴瘤

程序性死亡-1抑制剂治疗复发或难治性经典型霍奇金淋巴瘤的疗效与安全性

[Efficacy and safety of programmed death-1 inhibitor in the treatment of relapsed/refractory classical Hodgkin's lymphoma].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2023-01-01

该回顾性单中心研究纳入35例复发或难治性经典型霍奇金淋巴瘤患者,17例接受PD-1抑制剂单药治疗,18例接受PD-1抑制剂联合化疗;总体客观缓解率为80.0%、完全缓解率为62.9%;序贯自体造血干细胞移植者4年无进展生存率显著高于未序贯移植者(100% vs 53.5%,P=0.041)。

要点

  • PD-1抑制剂单药或联合化疗在R/R cHL中客观缓解率为80.0%,完全缓解率为62.9%。
  • PD-1抑制剂联合化疗组客观缓解率94.4%、完全缓解率66.7%,单药组分别为64.7%和58.8%。
  • 序贯auto-HSCT者4年PFS率100% vs 未序贯者53.5%(P=0.041)。

核心结论

  • PD-1抑制剂治疗R/R cHL安全、有效。
  • PD-1抑制剂联合化疗显著提高缓解率。
  • 对于挽救治疗敏感的患者,auto-HSCT巩固治疗进一步改善长期生存。

研究设计与样本

  • 回顾性、单中心研究,纳入2016年9月至2020年12月就诊于中国医学科学院血液病医院的35例R/R cHL患者。
  • 17例接受PD-1抑制剂单药治疗(PD-1抑制剂组),18例接受PD-1抑制剂联合化疗(PD-1抑制剂+化疗组)。
  • 回顾性分析临床资料和随访数据,采用Kaplan-Meier法和Cox比例风险模型进行生存分析。

主要发现

  • 35例患者中位年龄29岁(范围11~61岁),男性占54.3%,Ann Arbor分期进展期占62.9%,伴结外侵犯占48.6%。
  • PD-1抑制剂治疗前中位治疗线数为2线(范围1~3线)。
  • 28例患者获得客观缓解(其中22例为完全缓解),总体客观缓解率80.0%、完全缓解率62.9%。
  • PD-1抑制剂单药组客观缓解率64.7%、完全缓解率58.8%;PD-1抑制剂联合化疗组客观缓解率94.4%、完全缓解率66.7%。
  • 18例患者序贯auto-HSCT(13例完全缓解和5例部分缓解),其中8例auto-HSCT后给予PD-1抑制剂单药巩固治疗;移植后患者均获得并维持完全缓解状态,与未序贯auto-HSCT的患者相比无进展生存率显著升高(4年PFS率分别为100%和53.5%,P=0.041)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: This retrospective, single-center study aimed to evaluate the efficacy and safety of programmed death-1 (PD-1) inhibitors, either as monotherapy or in combination with chemotherapy, in the management of relapse/refractory classical Hodgkin's lymphoma (R/R cHL) . Methods: A total of 35 patients with R/R cHL who received treatment at the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College from September 2016 to December 2020 were enrolled in this study. Among them, 17 patients received PD-1 inhibitor monotherapy (PD-1 inhibitor group), while 18 patients received a combination of PD-1 inhibitor and chemotherapy (PD-1 inhibitor + chemotherapy group). Clinical data and follow-up information were retrospectively analyzed, and survival analysis was conducted using the Kaplan-Meier method and Cox proportional hazards model. Results: The median age of the 35 patients with R/R cHL was 29 years (range: 11-61 years), with 54.3% being male. According to the Ann Arbor staging system, 62.9% of patients presented with advanced (stage Ⅲ/Ⅳ) disease, and 48.6% had extranodal involvement. Before PD-1 inhibitor therapy, the median number of prior lines of therapy was 2 (range: 1-3). Objective responses were observed in 28 patients, including 22 complete response (CR) cases, resulting in an overall response rate (ORR) of 80.0% and a CR rate of 62.9%. Specifically, the ORR and CR rates were 64.7% and 58.8%, respectively, in the PD-1 inhibitor group and 94.4% and 66.7%, respectively, in the PD-1 inhibitor + chemotherapy group. Among the 18 patients who underwent sequential autologous hematopoietic stem cell transplantation (auto-HSCT) [13 CR and five partial response (PR) cases], eight patients received PD-1 inhibitor therapy after auto-HSCT as consolidation therapy. All patients maintained a CR status after transplantation, and they exhibited significantly improved progression-free survival (PFS) rates compared with those who did not undergo sequential auto-HSCT (4-year PFS rates: 100% vs 53.5% ; P=0.041). The incidence of immune-related adverse events was 29%, with only one patient experiencing grade≥3 adverse reactions, which indicated a favorable safety profile for the treatment approach. Conclusions: PD-1 inhibitor monotherapy demonstrates notable efficacy and sustained response in patients with R/R cHL. PD-1 inhibitors combined with chemotherapy significantly improve response rates. Additionally, for salvage therapy-sensitive patients, consolidation treatment with PD-1 inhibitors after auto-HSCT exhibits the potential for prolonging PFS. 目的: 回顾性分析程序性细胞死亡蛋白-1(programmed cell death protein-1,PD-1)抑制剂单药或联合化疗治疗复发或难治性经典型霍奇金淋巴瘤(R/R cHL)的疗效和安全性。 方法: 共纳入2016年9月至2020年12月就诊于中国医学科学院血液病医院的35例R/R cHL患者,其中17例给予PD-1抑制剂单药治疗,另18例接受PD-1抑制剂联合化疗。回顾性分析其临床资料和随访数据,采用Kaplan-Meier法和Cox比例风险模型进行生存分析。 结果: 35例R/R cHL患者中位年龄29(11~61)岁,男性占54.3%,62.9%的患者Ann Arbor分期为进展期,48.6%伴有结外侵犯。PD-1抑制剂治疗前的中位治疗线数为2(1~3)线。28例患者获得客观缓解[其中22例为完全缓解(CR)],客观缓解率(ORR)和CR率分别为80.0%和62.9%;其中PD-1单药治疗组的ORR和CR率分别为64.7%和58.8%,PD-1联合化疗组的ORR和CR率分别为94.4%和66.7%。18例[13例CR和5例部分缓解(PR)]患者序贯自体造血干细胞移植(auto-HSCT)治疗,其中8例患者auto-HSCT后给予PD-1抑制剂单药巩固治疗;移植后患者均获得并维持CR状态,与未序贯auto-HSCT的患者相比无进展生存(PFS)率显著升高(4年PFS率分别为100%和53.5%,P=0.041)。免疫相关的不良事件发生率为29%,仅1例患者出现≥3级不良反应,整体安全性良好。 结论: PD-1抑制剂治疗R/R cHL安全、有效,PD-1抑制剂联合化疗显著提高缓解率。对于挽救治疗敏感的患者,auto-HSCT巩固治疗进一步改善长期生存。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Shan DD, Liu HM, Liu W, et al. [Efficacy and safety of programmed death-1 inhibitor in the treatment of relapsed/refractory classical Hodgkin's lymphoma]. Zhonghua Xue Ye Xue Za Zhi. 2023. PMID: 37749034. doi:10.3760/cma.j.issn.0253-2727.2023.07.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。